Axsome Therapeutics stock hits 52-week low at 123.41 USD
Covered in this story
Analyst targets on Axsome Therapeutics Inc
- RBC Capital Markets: $156 → $295 by Oct 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AXSM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Axsome Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.